Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
about
Histone Deacetylases and Their Inhibition in Candida SpeciesEmerging drugs and vaccines for candidemiaHistone-modifying enzymes, histone modifications and histone chaperones in nucleosome assembly: Lessons learned from Rtt109 histone acetyltransferasesIdentification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus.HOS2 and HDA1 encode histone deacetylases with opposing roles in Candida albicans morphogenesis.Functional characterization of Candida albicans Hos2 histone deacetylase.Regulatory circuitry governing fungal development, drug resistance, and disease.Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis.Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus speciesThe challenge of managing fusariosisExploring the molecular basis of antifungal synergies using genome-wide approaches.Fungal KATs/KDACs: A New Highway to Better Antifungal Drugs?Extensive functional redundancy in the regulation of Candida albicans drug resistance and morphogenesis by lysine deacetylases Hos2, Hda1, Rpd3 and Rpd31.Combinatorial strategies for combating invasive fungal infections.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Small-molecule chromatin-modifying agents: therapeutic applications.Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus.Cryptococcal therapies and drug targets: the old, the new and the promising.Histone deacetylases inhibitors effects on Cryptococcus neoformans major virulence phenotypesThe anti-Aspergillus drug pipeline: Is the glass half full or empty?A Class 1 Histone Deacetylase with Potential as an Antifungal Target.Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance.The antifungal pipeline: a reality check.Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.Novel hydroxamates potentiated in vitro activity of fluconazole against Candida albicans.Histone deacetylases: Targets for antifungal drug development.Targeting chromatin in fungal pathogens as a novel therapeutic strategy: histone modification gets infectious.Candida albicans Heat Shock Proteins and Hsps-Associated Signaling Pathways as Potential Antifungal Targets.Histone acetyltransferase encoded by NGG1 is required for morphological conversion and virulence of Candida albicans.The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans.Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.Diagnostic Aspects of Veterinary and Human Aspergillosis.A Class 1 Histone Deacetylase as Major Regulator of Secondary Metabolite Production in
P2860
Q26740146-FF065F02-2858-4518-94AA-3E209DE80BECQ26828993-13BCE033-FCB7-48F7-B8F4-CEB4447FF2D1Q27003952-BF6CDC2C-AAA2-4913-8F3A-10F31ABF2433Q33622943-0B8FA15D-1219-402B-8D0F-ADB2C2F5808EQ33668741-117E5BD1-E283-496E-9D2E-212FD8AD3712Q33950770-C36A2CB3-1E3E-4CC9-AC49-8E5677D8E234Q34190284-20F740E0-4728-4676-857C-B8B918B825E5Q35087299-4E339CB5-501E-4E59-97DA-B95751D469D0Q35214605-BBD41991-5884-4154-B030-2CEA5DC0BB78Q35693680-AEDEB44A-5A19-4AF3-883D-823196584399Q35854979-3C9B227F-9F82-4600-9809-CFEACD48CD06Q36188969-B34D5BC2-9D2C-4409-8F57-7AC8F4A5EB8CQ37629735-8FA4FBAD-B67E-4B53-BE58-37B0E699D09CQ37705303-60EAB793-5B40-4133-8738-4CAC00DF92EBQ37918556-6FD5E3D7-A3BD-4C7F-8266-3D3EC4671A9EQ37961728-1BCE0A8D-C592-4FCE-89B3-9743DE4F2D35Q38253077-0707CFE4-B684-4A52-80BA-8BF0640BD6D4Q38779568-80310346-3A3D-49B2-B20D-C965E59152DBQ38919839-D7A0168F-A2E2-4721-9680-C9A2815EEE2DQ38937577-DA51B132-47C1-4647-93A4-CB59BDEB90ECQ39226155-E6735C0B-718C-4C01-B156-C640F31BA416Q39260998-2F53CB3C-F9EA-4116-957C-C121DE8625E9Q39299949-4CF65A70-CF73-4D4D-9E66-6A76B96BA046Q40045666-E0434891-AAE2-4539-B1FA-A09FF3D5A4FDQ41967401-A29DBC0C-F72F-451F-89E2-87A5E348F700Q43077777-DB1E522A-01ED-4C9A-B834-28D3AC5F5401Q45205699-3C30C0B8-05E0-4A05-A4F3-E95089C66333Q47220163-B3F60E47-8570-43CE-94AB-989108BAE2A7Q47855340-E87648A4-31EA-42E2-A741-7658B1A818C2Q53561135-D030C765-8D9C-4FE5-BB71-74E4435C223EQ55098668-644CE764-DF66-4CFB-9486-E49D4D08FB0CQ55471038-7C13072D-7513-4D49-8361-B10941746F1AQ57072796-FDA238B1-8724-4D5A-9754-305C693C4D71
P2860
Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Activity of MGCD290, a Hos2 hi ...... pportunistic fungal pathogens.
@en
type
label
Activity of MGCD290, a Hos2 hi ...... pportunistic fungal pathogens.
@en
prefLabel
Activity of MGCD290, a Hos2 hi ...... pportunistic fungal pathogens.
@en
P2093
P2860
P356
P1476
Activity of MGCD290, a Hos2 hi ...... opportunistic fungal pathogens
@en
P2093
J M Besterman
L A Martell
M A Pfaller
N Georgopapadakou
S A Messer
P2860
P304
P356
10.1128/JCM.00618-09
P407
P577
2009-09-30T00:00:00Z